Literature DB >> 26284508

In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Ryan Taschuk1, Jacques Van der Merwe, Kristen Marciniuk, Andrew Potter, Neil Cashman, Philip Griebel, Scott Napper.   

Abstract

Prion diseases reflect the misfolding of a self-protein (PrP(C)) into an infectious, pathological isomer (PrP(Sc)). By targeting epitopes uniquely exposed by misfolding, our group developed PrP(Sc)-specific vaccines to 3 disease specific epitopes (DSEs). Here, antibodies induced by individual DSE vaccines are evaluated for their capacity to neutralize prions in vitro. For both purified antibodies and immunoreactive sera, the PrP(Sc)-specific antibodies were equally effective in neutralizing prions. Further, there was no significant increase in neutralizing activity when multiple DSEs were targeted within an assay. At a low antibody concentration, the PrP(Sc)-specific antibodies matched the neutralization achieved by an antibody that may act via both PrP(C) and PrP(Sc). At higher doses, however, this pan-specific antibody was more effective, potentially due to a combined deactivation of PrP(Sc) and depletion of PrP(C).

Entities:  

Keywords:  antibodies; antibody neutralization; disease specific epitopes; prion; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26284508      PMCID: PMC4601508          DOI: 10.1080/19336896.2015.1071761

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  31 in total

1.  Immunomodulation of the human prion peptide 106-126 aggregation.

Authors:  E Hanan; O Goren; M Eshkenazy; B Solomon
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

2.  A prion protein epitope selective for the pathologically misfolded conformation.

Authors:  Eustache Paramithiotis; Marc Pinard; Trebor Lawton; Sylvie LaBoissiere; Valerie L Leathers; Wen-Quan Zou; Lisa A Estey; Julie Lamontagne; Marty T Lehto; Leslie H Kondejewski; Gregory P Francoeur; Maria Papadopoulos; Ashkan Haghighat; Stephen J Spatz; Mark Head; Robert Will; James Ironside; Katherine O'Rourke; Quentin Tonelli; Harry C Ledebur; Avi Chakrabartty; Neil R Cashman
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 3.  Chronic wasting disease of cervids: current knowledge and future perspectives.

Authors:  Nicholas J Haley; Edward A Hoover
Journal:  Annu Rev Anim Biosci       Date:  2014-10-02       Impact factor: 8.923

4.  Induction of antibodies against murine full-length prion protein in wild-type mice.

Authors:  Michael F Koller; Thomas Grau; Philipp Christen
Journal:  J Neuroimmunol       Date:  2002-11       Impact factor: 3.478

5.  The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein.

Authors:  Tiziana Sonati; Regina R Reimann; Jeppe Falsig; Pravas Kumar Baral; Tracy O'Connor; Simone Hornemann; Sine Yaganoglu; Bei Li; Uli S Herrmann; Barbara Wieland; Mridula Swayampakula; Muhammad Hafizur Rahman; Dipankar Das; Nat Kav; Roland Riek; Pawel P Liberski; Michael N G James; Adriano Aguzzi
Journal:  Nature       Date:  2013-07-31       Impact factor: 49.962

Review 6.  Immunotherapy for prion diseases: opportunities and obstacles.

Authors:  Li Li; Scott Napper; Neil R Cashman
Journal:  Immunotherapy       Date:  2010-03       Impact factor: 4.196

Review 7.  Promising developments bringing prion diseases closer to therapy and prophylaxis.

Authors:  Sabine Gilch; Hermann M Schätzl
Journal:  Trends Mol Med       Date:  2003-09       Impact factor: 11.951

8.  Immunization delays the onset of prion disease in mice.

Authors:  Einar M Sigurdsson; David R Brown; Maki Daniels; Richard J Kascsak; Regina Kascsak; Richard Carp; Harry C Meeker; Blas Frangione; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein.

Authors:  E Hanan; S A Priola; B Solomon
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 4.231

Review 10.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

View more
  4 in total

1.  Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains.

Authors:  Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  Protein Eng Des Sel       Date:  2016-11-29       Impact factor: 1.650

Review 2.  Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.

Authors:  Buyong Ma; Jun Zhao; Ruth Nussinov
Journal:  Biochim Biophys Acta       Date:  2016-06-03

Review 3.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

4.  Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease.

Authors:  Ryan Taschuk; Erin Scruten; Murray Woodbury; Neil Cashman; Andrew Potter; Philip Griebel; Suresh K Tikoo; Scott Napper
Journal:  Prion       Date:  2017-09-03       Impact factor: 3.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.